SAFETY DATA SHEET

Pembrolizumab Liquid Formulation

Version: 4.10  Revision Date: 09/13/2019  SDS Number: 49543-00015  Date of last issue: 24.04.2019
Date of first issue: 23.01.2015

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Pembrolizumab Liquid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 26 Talavera Road, Talavera Corp Centre, Macquarie Park
New South Wales, 2113 Australia
Telephone: (61)-02-8988-8000
Emergency telephone number: (61)-02-8988-8000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity: Category 1B
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Immune system)

GHS label elements
Hazard pictograms:

Signal word: Danger
Hazard statements:
H360D May damage the unborn child.
H373 May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Precautionary statements: Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P281 Use personal protective equipment as required.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.
SAFETY DATA SHEET

Pembrolizumab Liquid Formulation

Version: 4.10  Revision Date: 09/13/2019  SDS Number: 49543-00015  Date of last issue: 24.04.2019
Date of first issue: 23.01.2015

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mixture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES
SAFETY DATA SHEET

Pembrolizumab Liquid Formulation

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing.
Do not breathe vapours or spray mist. 
Do not swallow. 
Avoid contact with eyes. 
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment 
Keep container tightly closed. 
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. 
When using do not eat, drink or smoke. 
Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers. 
Store locked up. 
Keep tightly closed. 
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types: 
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information: This value is for inhalable dust containing no asbestos and &lt; 1% crystalline silica</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>TWA</td>
<td>75 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures : Minimize workplace exposure concentrations. 
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. 
Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to
chemicals of the aforementioned protective gloves with the
glove manufacturer. Wash hands before breaks and at the
end of workday.

Eye protection  : Wear the following personal protective equipment:
                 Safety glasses

Skin and body protection  : Select appropriate protective clothing based on chemical
                           resistance data and an assessment of the local exposure
                           potential.
                           Skin contact must be avoided by using impervious protective
                           clothing (gloves, aprons, boots, etc).

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance  : suspension

Colour  : Colorless to pale yellow

Odour  : No data available

Odour Threshold  : No data available

pH  : 5.5

Melting point/freezing point  : No data available

Initial boiling point and boiling range  : No data available

Flash point  : No data available

Evaporation rate  : No data available

Flammability (solid, gas)  : Not applicable

Flammability (liquids)  : No data available

Upper explosion limit / Upper flammability limit  : No data available

Lower explosion limit / Lower flammability limit  : No data available

Vapour pressure  : No data available

Relative vapour density  : No data available

Relative density  : No data available

Density  : No data available

Solubility(ies)
Water solubility  : No data available

Partition coefficient: n-octanol/water  : No data available

Auto-ignition temperature  : No data available
SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Compatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Sucrose:
Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage the unborn child.

Components:

Pembrolizumab:
Reproductive toxicity - Assessment: May damage the unborn child., Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Components:

Pembrolizumab:
Target Organs: Immune system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Pembrolizumab:
Species: Monkey
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Pembrolizumab:
Inhalation
Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest, May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:
Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:
Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Revision Date : 09/13/2019
Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.
ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average
SAFETY DATA SHEET

Pembrolizumab Liquid Formulation

Version 4.10  Revision Date: 09/13/2019
SDS Number: 49543-00015  Date of last issue: 24.04.2019

Date of first issue: 23.01.2015

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

AU / EN